NephroGenex (NRX) Tops Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
NephroGenex Reports Third Quarter 2015 Financial Results
November 11, 2015 4:05 PM ESTConference call and webcast to be held Thursday, November 12, 2015 at 8:30 a.m. EST
RALEIGH, N.C.--(BUSINESS WIRE)-- NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2015.
During the third quarter of 2015, we continued to make progress in advancing our Phase 3 study of oral Pyridorin for the treatment of diabetic nephropathy, adding new clinical sites and increasing the number of randomized patients. We remain on track to complete... More
